Akari Therapeutics AKTX

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.02 (+2.05%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Akari Therapeutics (AKTX)
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $0.925

  • Market Cap

    $24.49 Million

  • Price-Earnings Ratio

    Infinity

  • Total Outstanding Shares

    49.52 Billion Shares

  • Total Employees

    12

  • Dividend

    No dividend

  • IPO Date

    December 7, 2012

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    American Depository Receipt Common

  • Headquarters

    22 boston wharf road, Boston, MA, 02210

  • Homepage

    https://www.akaritx.com

Historical Stock Splits

If you bought 200 shares of AKTX before September 17, 2015, you'd have 1 share today.
Execution DateSplit Amount
August 17, 20231-for-20 (Reverse Split)
September 17, 20151-for-10 (Reverse Split)

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$1.93 Million
Net Cash Flow From Financing Activities, Continuing$-443,000
Net Cash Flow From Operating Activities, Continuing$-1.49 Million
Net Cash Flow From Investing Activities, Continuing$1.93 Million
Net Cash Flow, Continuing$-4,000
Net Cash Flow From Operating Activities$-1.49 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Income/Loss$-2.90 Million
Basic Average Shares$24.39 Billion
Net Income/Loss Attributable To Parent$-2.90 Million
Income/Loss From Continuing Operations After Tax$-2.90 Million
Diluted Earnings Per Share$0
Operating Income/Loss$-2.93 Million

Comprehensive Income

July 1, 2024 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$-3.07 Million
Comprehensive Income/Loss Attributable To Parent$-3.07 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss$-3.07 Million
Other Comprehensive Income/Loss Attributable To Parent$-177,000

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Equity$-6.69 Million
Equity Attributable To Parent$-6.69 Million
Prepaid Expenses$396,000
Equity Attributable To Noncontrolling Interest$0
Noncurrent Liabilities$0
Assets$2.73 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AKTX from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.